Similarly, in vitro observations in oxaliplatin-resistant HCT116 and SW480 colorectal cancer cells further evidenced that ANXA3-knockdown has significantly impeded the phosphorylation of ERK and JNK, which led to decreased cell viability and BrdU incorporation as well as increased apoptosis and impaired migration and invasion abilities (Xu et al., 2019). Here, ANXA3 is linked to colorectal cancer.